Zhouao Zhang

6PUBLICATIONS
34CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)AllergyMedical devicesMedical biochemistry - amino acids and metabolites
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Jan 02, 2026
BCMA/CD19 CAR T cell therapy for refractory myasthenia gravis: Proteomic signatures and single-cell transcriptomics of disease flares.

Xiaoyu Huang, Zhouao Zhang, Dan Liu

|Nov 28, 2025
Olink Proteomics Analysis Reveals Heterogeneous Responses to FcRn Blockade in Anti-AChR Antibody-Positive Myasthenia Gravis: FGF-19 as a Novel Biomarker.

Tiancheng Luo, Deyou Peng, Zhouao Zhang

|Feb 20, 2025
Patterns and predictors of therapeutic response to efgartigimod in acetylcholine receptor-antibody generalized myasthenia gravis subtypes.

Lei Jin, Zhangyu Zou, Qinzhou Wang

|Jul 08, 2024
Efgartigimod for generalized myasthenia gravis: A multicenter real-world cohort study in China.

Sushan Luo, Qilong Jiang, Wenshuang Zeng

|May 30, 2024
Rescue treatment with add-on efgartigimod in a patient with impending myasthenic crisis: a case report.

Zhouao Zhang, Mingjin Yang, Tiancheng Luo

|May 09, 2023
Plasma C18:0-ceramide is a novel potential biomarker for disease severity in myasthenia gravis.

Zhouao Zhang, Xiaoyu Huang, Xue Du

Pageof 1

Frequent Collaborators

4 joint publications

Yong Zhang

3 joint publications

Yong Zhang

2 joint publications

Mingjin Yang

2 joint publications

Xue Du